WebJan 31, 2024 · The total number of HSAs as of January 31, 2024 was 5.8 million, an increase of 8%, from 5.3 million as of January 31, 2024. The Company closed its fiscal … Web22 hours ago · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for HealthEquity (HQY)
HealthEquity Reports Fiscal Year and Fourth Quarter Ended
WebJan 31, 2024 · Non-GAAP net income in the range of $125 million and $128 million; and Non-GAAP net income per diluted share range between $1.67 and $1.71 (based on an estimated 75 million diluted weighted-average shares outstanding). The Company also provided fiscal year 2024 revenue guidance in the range of $740 million to $750 million. WebHealthEquity revenue from 2014 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. HealthEquity provides integrated solutions for ... elite dna therapy tampa
HealthEquity Reports Year-End Sales Metrics
WebDec 8, 2024 · HealthEquity reported a net loss of $1.6 million, or $0.02 per diluted share, and non-GAAP net income of $32.4 million, or $0.38 per diluted share, for the third quarter ended October 31, 2024. ... Its outlook for non-GAAP net income, calculated using the method described below, is between $106 million and $114 million, resulting in non … WebJan 31, 2024 · Net income in the range of $39 million and $41 million; Adjusted EBITDA in the range of $194 million and $196 million; Non-GAAP net income in the range of $117 … elite dna therapy services venice fl